ReviewPeerJ2025
Natural products as promising therapeutics for fine particulate matter-induced skin damage: a review of pre-clinical studies on skin inflammation and barrier dysfunction.
Review in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Particulate Matter-Induced Skin Injury: A Dual-Pathway AhR-Nrf2 Framework for Epidermal Homeostasis and Therapeutic Targeting.International journal of molecular sciences · 2026Review
- Research progress on the mechanisms of Panax ginseng and its active components in maintaining skin homeostasis and disease intervention.Chinese medicine · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Exploration of Natural Adsorbents for Applications in Pollution-Reducing Cosmetic Formulations.Gels (Basel, Switzerland) · 2026Review
- Integrative multi-omics and computational modeling reveal RPL22-driven skin aging mechanisms under PM2.5 exposure and identify high-stability natural inhibitors.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dietary Polyphenols (Flavonoids) Derived from Plants for Use in Therapeutic Health: Antioxidant Performance, ROS, Molecular Mechanisms, and Bioavailability Limitations.International journal of molecular sciences · 2026Review
- Particulate matter exposure induces maternal scalp hair loss after birth in C57/B6 mouse via alteration of inflammatory and apoptotic pathways.Frontiers in endocrinology · 2026Article
- A Systemic Pathophysiological View of Sensitive Skin Revealed by Proteomics: Beyond Barrier and Inflammation.Journal of cosmetic dermatology · 2026Article
- Functional Features of Senescent Cells and Implications for Therapy.International journal of molecular sciences · 2025Review
- Neuroprotective potential of quercetin in Alzheimer's disease: targeting oxidative stress, mitochondrial dysfunction, and amyloid-β aggregation.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Particulate matter less than 2.5 µm (PM2.5) is a significant air pollutant and is linked to an increased risk of health conditions, including skin diseases. The skin, as the first barrier and the largest organ, is primarily damaged by PM2.5 through different pathways. Several studies have shown that PM2.5 upregulates inflammatory responses through the excessive production of reactive oxygen species (ROS) and several inflammatory cytokines, leading to PM2.5-induced skin damage. The ROS/mitogen-activated protein kinase (MAPK) and Cyclooxygenase-2-Prostaglandin E2 (COX2/PGE2) inflammatory pathways are activated by free radical scavenging and phase II detoxification. Natural products have been suggested as therapeutic agents for mitigating PM2.5-induced skin damage. Objectives: We elaborate on the mechanisms of action of natural products and their functions as protectants against environmental skin diseases. This review highlights the optimal doses of natural products for clinical study, which may benefit dermatologists, molecular biologists, clinicians, and healthcare professionals in preventive and alternative medicine. Methodology: The available scientific literature published between 1999 and 2024 was searched using PubMed and Google Scholar. Multiple keywords related to the topic were used. Only 41 of the screened articles were chosen for this review, as they were the most relevant publications on the topic of the preventive advantages of natural products and specific pathways targeting PM2.5-induced skin injury. All relevant articles meeting the criteria of being original full articles and written in English were included. Results: This review summarized the natural products, including phenolic/polyphenolic compounds and flavonoids, that can act as anti-inflammatory and antioxidant agents by protecting the skin against oxidative stress, inhibiting enzymes that promote free radical formation, enhancing antioxidant enzyme activity, and reducing overall ROS formation. Several natural products have demonstrated efficacy in alleviating intracellular ROS, oxidative stress, mitochondrial dysfunction, autophagy, and apoptosis caused by PM2.5. In addition, phytochemical agents support the restoration of the skin wound healing process and muscle contraction impaired by environmental pollutants, such as PM2.5 and UV rays. Conclusion: This review highlights promising natural agents that can protect against environment-mediated health problems by focusing on their mechanisms of action. Particular emphasis is placed on antioxidant and anti-inflammatory compounds, including sulforaphane, hesperidin, quercetin, catechin, diphloroethohydroxycarmalol, resveratrol, and ginsenoside, which have become interesting candidates as nutraceuticals due to their potential to reduce reliance on conventional medicines. However, the low stability and bioavailability of natural products remain significant challenges to their clinical use; therefore, further research and development are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.